NALOXEGOL OXALATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C34H53NO11.C2H2O4
Molecular Weight	741.8196
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

OC(=O)C(O)=O.COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC=C)=C(O)C=C4

InChI

InChIKey=MNYIRXLCPODKLG-VUTNLTPYSA-N

InChI=1S/C34H53NO11.C2H2O4/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2;3-1(4)2(5)6/h3-5,28-29,32,36-37H,1,6-25H2,2H3;(H,3,4)(H,5,6)/t28-,29+,32-,33-,34+;/m0./s1

HIDE SMILES / InChI

Description

MOVANTIK (naloxegol) is a peripherally-acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic noncancer pain. It is being investigated for the treatment of constipation as a side effect of prescription opioid pain medicines.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mu-type opioid receptor 61	Antagonist 2,778		7.4 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Opioid-induced constipation 8	Secondary		Approved 8,429	MOVANTIK

C_max

Value	Dose	Analyte	Population
81.1 ng/mL	25 mg 1 times / day multiple, oral	NALOXEGOL OXALATE plasma	Homo sapiens
8 ng/mL	5 mg 1 times / day multiple, oral	NALOXEGOL OXALATE plasma	Homo sapiens
100 ng/mL	50 mg 1 times / day multiple, oral	NALOXEGOL OXALATE plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
334.8 ng × h/mL	25 mg 1 times / day multiple, oral	NALOXEGOL OXALATE plasma	Homo sapiens
39 ng × h/mL	5 mg 1 times / day multiple, oral	NALOXEGOL OXALATE plasma	Homo sapiens
403.6 ng × h/mL	50 mg 1 times / day multiple, oral	NALOXEGOL OXALATE plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
14.1 h	25 mg 1 times / day multiple, oral	NALOXEGOL OXALATE plasma	Homo sapiens
17.4 h	5 mg 1 times / day multiple, oral	NALOXEGOL OXALATE plasma	Homo sapiens
20.3 h	50 mg 1 times / day multiple, oral	NALOXEGOL OXALATE plasma	Homo sapiens
6 h	unknown, unknown	NALOXEGOL OXALATE plasma	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
95.8%	unknown, unknown		NALOXEGOL OXALATE plasma	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
1000 mg single, oral Highest studied dose	healthy, 18 - 45 years n = 6	Other AEs: Gastrointestinal disorder (NOS), Nausea...
250 mg 2 times / day steady, oral Highest studied dose	healthy, 59 years (range: 18 - 65 years) n = 6	Other AEs: Myalgia, Restless leg syndrome...
25 mg 1 times / day steady, oral Recommended	unhealthy, adult n = 446	Disc. AE: Diarrhea, Abdominal pain...
12.5 mg 1 times / day steady, oral	unhealthy, adult n = 441	Disc. AE: Diarrhea, Abdominal pain...

Showing 1 to 4 of 4 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Dizziness	16.7%	1000 mg single, oral Highest studied dose	healthy, 18 - 45 years n = 6
Gastrointestinal disorder (NOS)	16.7%	1000 mg single, oral Highest studied dose	healthy, 18 - 45 years n = 6
Nausea	16.7%	1000 mg single, oral Highest studied dose	healthy, 18 - 45 years n = 6
Somnolence	16.7%	1000 mg single, oral Highest studied dose	healthy, 18 - 45 years n = 6
CNS disorder (NOS)	33.3%	1000 mg single, oral Highest studied dose	healthy, 18 - 45 years n = 6

Showing 1 to 5 of 30 entries

Previous1 2 3 4 5 6Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1,587 inducer 781 substrate 1,737	inhibitor 1,767	inhibitor 1,852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1,524 CYP2C19 1,478 P-gp 1,461 BCRP 699 OAT1 599 OAT3 642 OCT2 647 OATP1B1 788 OATP1B3 706	CYP3A 191 P-gp 1,537 OATP1B1 406 BCRP 561	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Show entries

Target	Modality	Activity
BCRP 773	inhibitor 3,277	no [IC50 >100 uM]
OAT1 603	inhibitor 3,277	no [IC50 >100 uM]
OAT3 644	inhibitor 3,277	no [IC50 >100 uM]
OATP1B1 803	inhibitor 3,277	no [IC50 >100 uM]
OATP1B3 715	inhibitor 3,277	no [IC50 >100 uM]

Showing 1 to 5 of 15 entries

Previous1 2 3Next

Drug as victim

Show entries

Target	Modality	Activity	Clinical evidence
BCRP 561	substrate 3,367	no
OATP1B1 406	substrate 3,367	no
CYP3A 191	substrate 3,367	yes
CYP3A4 1,737	substrate 3,367	yes	yes (co-administration study)
P-gp 1,537	substrate 3,367	yes	yes (co-administration study)

Showing 1 to 5 of 5 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:82975	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:82975
ChemicalBook	CB32614743	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32614743
ZINC	ZINC000095564694	http://zinc15.docking.org/substances/ZINC000095564694

Showing 1 to 3 of 3 entries

Previous1Next

PubMed

Title	Date	PubMed
New approaches to the treatment of opioid-induced constipation.	2008 Aug	18924451

Patents

Sample Use Guides

In Vivo Use Guide

The recommended MOVANTIK dosage is 25 mg once daily in the morning. If patients are not able to tolerate MOVANTIK, reduce the dosage to 12.5 mg once daily.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Show entries

Name

Type

Language

NALOXEGOL OXALATE

Official Name

English

MOVENTIG

Brand Name

English

Naloxegol oxalate [WHO-DD]

Common Name

English

AZ13337019 OXALATE

Code

English

NKTR-118-OXALATE

Code

English

Showing 1 to 5 of 14 entries

Previous1 2 3Next

Show entries

Classification Tree

Code System

Code

SIGNS AND SYMPTOMS, DIGESTIVE

EMA ASSESSMENT REPORTS

MOVENTIG (AUTHORIZED: CONSTIPATION)

SUBSTANCE-RELATED DISORDERS

EMA ASSESSMENT REPORTS

MOVENTIG (AUTHORIZED: OPIOID-RELATED DISORDERS)

Agent Affecting Nervous System

NCI_THESAURUS

C681

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Code System

Code

Type

Description

SMS_ID

100000152159

PRIMARY

EPA CompTox

DTXSID50159395

PRIMARY

FDA UNII

65I14TNM33

PRIMARY

PUBCHEM

56959086

PRIMARY

EVMPD

SUB126717

PRIMARY

Showing 1 to 5 of 13 entries

Previous1 2 3Next

ACTIVE MOIETY


					44T7335BKE

NALOXEGOL

SUBSTANCE RECORD


					65I14TNM33

NALOXEGOL OXALATE

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound

Drug as perpetrator